廣濟藥業(000952.SZ):2019年淨利預降44.68%-56.33%
格隆匯1月17日丨廣濟藥業(000952.SZ)披露2019年年度業績預告,公司預計2019年1-12月歸屬於上市公司股東的淨利潤為7500萬元-9500萬元,同比下降44.68%-56.33%;基本每股收益0.302元-0.382元。業績變動原因如下:
受“非洲豬瘟”事件影響,2019年度維生素市場行情低迷,行業競爭加劇,主導產品核黃素銷售價格處於市場週期的低價格水平,銷售價格同比2018年度大幅下滑,導致淨利潤的波動幅度較大。公司主導產品80%飼料級VB2的2019年度市場銷售均價與2014年度市場銷售均價持平,維持在100-110元/kg,2014年公司營業利潤虧損2.26億元,但2019年依然保持較高的利潤水平,這得益於公司持續的工藝優化、技術改進、成本控制及精細化管理,相較於2014年,公司80%飼料級VB2產品單位成本大幅下降。公司將持續加大研發投入力度、加大技術創新、加強經營管理,提升公司核心競爭力,確保公司高質量發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.